Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study

Cardiovascular Diabetology
Chun-Ting YangShihchen Kuo

Abstract

Current evidence about the cardiovascular safety of glucagon-like peptide-1 receptor agonist (GLP-1ra) possesses limited generalizability to real-world patients with type 2 diabetes (T2D) in usual practice. This study aimed to investigate the comparative cardiovascular safety of GLP-1ra in comparisons with dipeptidyl peptidase-4 inhibitor (DPP-4i), sulfonylurea (SU), and insulin in a real-world population with T2D. Adults with newly-diagnosed T2D were identified from Taiwan's National Health Insurance Research Database in 2003-2014. A prevalent new-user cohort design was adopted to include a broad representation of real-world T2D patients being treated with GLP-1ra. The between-group comparability of baseline patient characteristics was achieved by matching on (1) initiation time of study drugs, (2) prior exposure to glucose-lowering agents, and (3) diabetes severity and complications, comorbidities, and concomitant cardiovascular medications using propensity scores. The primary outcome was a composite of cardiovascular disease (CVD) events and assessed up to the end of 2015. Cox modeling was employed to assess the association between study drugs and outcomes. A total of 3195 GLP-1ra stable users was identified in 2011-2014. 18...Continue Reading

References

May 15, 1996·American Journal of Epidemiology·K A MatthewsP Plantinga
Feb 26, 2011·Pharmacoepidemiology and Drug Safety·Ching-Lan ChengMing Liang Lai
Nov 23, 2012·Diabetes Care·Samy Suissa, Laurent Azoulay
May 22, 2013·Diabetes Care·David M NathanUNKNOWN GRADE Study Research Group
Jun 14, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN LEADER Trial Investigators
Sep 10, 2016·Pharmacoepidemiology and Drug Safety·Samy SuissaSophie Dell'Aniello
Sep 17, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN SUSTAIN-6 Investigators
Jan 20, 2017·Expert Opinion on Drug Safety·Niels B DalsgaardFilip K Knop
Mar 12, 2018·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Marco Orsini FedericiKirsi Norrbacka
Dec 12, 2018·The Lancet. Diabetes & Endocrinology·Henrik SvanströmBjörn Pasternak
Dec 14, 2018·Cardiovascular Diabetology·Andrei C SpositoJosé Francisco Kerr Saraiva
Dec 19, 2018·Diabetes Care·UNKNOWN American Diabetes Association
Mar 23, 2019·Diabetes, Obesity & Metabolism·William HintonSimon de Lusignan
May 24, 2019·Clinical Epidemiology·Cheng-Yang HsiehEdward Chia-Cheng Lai
Jun 12, 2019·The New England Journal of Medicine·Mansoor HusainUNKNOWN PIONEER 6 Investigators

❮ Previous
Next ❯

Citations

Nov 19, 2020·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Mario Luca MorieriGian Paolo Fadini
Mar 16, 2021·Frontiers in Cardiovascular Medicine·Jing CuiYue Liu

❮ Previous
Next ❯

Software Mentioned

GLA

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.